home / stock / huma / huma quote
Last: | $8.201 |
---|---|
Change Percent: | -6.7% |
Open: | $8.58 |
Close: | $8.79 |
High: | $8.65 |
Low: | $7.91 |
Volume: | 3,773,434 |
Last Trade Date Time: | 07/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.201 | $8.58 | $8.79 | $8.65 | $7.91 | 3,773,434 | 07-17-2024 |
$8.79 | $8.84 | $8.79 | $8.99 | $8.1831 | 6,081,684 | 07-16-2024 |
$8.4 | $7.5 | $8.4 | $8.71 | $7.27 | 10,119,997 | 07-15-2024 |
$6.99 | $6.6 | $6.99 | $7 | $6.4125 | 3,471,051 | 07-12-2024 |
$6.45 | $5.895 | $6.45 | $6.47 | $5.82 | 3,189,166 | 07-11-2024 |
$5.72 | $5.97 | $5.72 | $6.2199 | $5.72 | 3,498,767 | 07-10-2024 |
$5.855 | $5.75 | $5.855 | $6.0699 | $5.52 | 2,709,267 | 07-09-2024 |
$5.67 | $5.37 | $5.67 | $5.89 | $5.345 | 3,714,781 | 07-08-2024 |
$5.27 | $5.72 | $5.27 | $5.87 | $5.26 | 3,028,033 | 07-05-2024 |
$5.67 | $5.1 | $5.67 | $5.85 | $5.09 | 2,432,053 | 07-04-2024 |
$5.67 | $5.1 | $5.67 | $5.85 | $5.09 | 2,432,053 | 07-03-2024 |
$5.11 | $5.63 | $5.11 | $5.68 | $5.05 | 3,262,781 | 07-02-2024 |
$5.37 | $5.36 | $5.37 | $6.3 | $5.05 | 9,067,415 | 07-01-2024 |
$4.8 | $4.72 | $4.8 | $4.88 | $4.6 | 8,265,958 | 06-28-2024 |
$4.7 | $4.95 | $4.7 | $5.11 | $4.65 | 2,495,924 | 06-27-2024 |
$5 | $4.93 | $5 | $5.105 | $4.85 | 1,834,945 | 06-26-2024 |
$4.93 | $5.1 | $4.93 | $5.22 | $4.92 | 3,169,946 | 06-25-2024 |
$5.1 | $5.15 | $5.1 | $5.32 | $5.05 | 2,414,452 | 06-24-2024 |
$5.17 | $5.22 | $5.17 | $5.36 | $5 | 6,835,415 | 06-21-2024 |
$5.24 | $5.71 | $5.24 | $5.79 | $5.17 | 4,504,380 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...